Showing results (111-120 of 167) with videos related to
Sort By:
Pageof 17
European Journal of Clinical Investigation|October 1, 1985
Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in manC Marone, F Muggli, W Lahn, et al.Clinical Pharmacokinetics|February 1, 1992
Fleroxacin clinical pharmacokineticsA E Stuck, D K Kim, F J FreyReviews of Infectious Diseases|November 1, 1989
Risk of infectious complications in patients taking glucocorticosteroidsA E Stuck, C E Minder, F J FreyHypertension (Dallas, Tex. : 1979)|December 26, 2001
In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licoriceP Ferrari, A Sansonnens, B Dick, et al.American Journal of Hospital Pharmacy|November 1, 1989
Clinical career ladders: Thomas Jefferson University HospitalJ E Smith, S L Sheaffer, B M FreyBritish Journal of Clinical Pharmacology|June 26, 1999
Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysisM Pfister, F Schaedeli, F J Frey, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 8, 2006
Successful kidney transplantation from donor with Marfan's syndromeS Farese, B Vogt, F J Frey, et al.Journal of the American Society of Nephrology : JASN|December 1, 1996
Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: the role of the transplanted kidneyC Wissmann, F J Frey, P Ferrari, et al.The American Journal of Physiology|April 1, 1996
Effects of growth hormone and IGF-I on glucocorticoid-induced protein catabolism in humansM Oehri, R Ninnis, J Girard, et al.Journal of Clinical Pharmacology|March 1, 1990
Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal functionM P Schoerlin, F F Horber, F J Frey, et al.Pageof 17